CN116004416B - Application of bifidobacterium bifidum from infant intestinal tract - Google Patents
Application of bifidobacterium bifidum from infant intestinal tract Download PDFInfo
- Publication number
- CN116004416B CN116004416B CN202210821655.XA CN202210821655A CN116004416B CN 116004416 B CN116004416 B CN 116004416B CN 202210821655 A CN202210821655 A CN 202210821655A CN 116004416 B CN116004416 B CN 116004416B
- Authority
- CN
- China
- Prior art keywords
- group
- intestinal
- bifidobacterium bifidum
- saline
- dss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186016 Bifidobacterium bifidum Species 0.000 title claims abstract description 28
- 229940002008 bifidobacterium bifidum Drugs 0.000 title claims abstract description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 21
- 230000000968 intestinal effect Effects 0.000 claims abstract description 33
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 24
- 230000007774 longterm Effects 0.000 claims abstract description 16
- 238000010276 construction Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 abstract description 21
- 238000002474 experimental method Methods 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 241000699670 Mus sp. Species 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 208000002551 irritable bowel syndrome Diseases 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 14
- 230000006378 damage Effects 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 229920003045 dextran sodium sulfate Polymers 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 241000192031 Ruminococcus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010053584 Neonatal pneumonia Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241001311541 Scardovia inopinata Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000033822 gland development Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of bifidobacterium bifidum from infant intestinal tracts, belongs to the field of biotechnology, and solves the problem that in the prior art, the construction of intestinal flora in early life is promoted by bifidobacterium from infant intestinal tracts so as to relieve symptoms of long-term inflammatory bowel diseases. The invention provides application of bifidobacterium bifidum BD-1 from infant intestinal tracts, which has the preservation number of CGMCCNO.24517 and is applied to preparation of medicines or foods with the effect of promoting construction of intestinal flora in early life. Animal experiments show that the bifidobacterium BD-1 is used in early life, so that the construction of intestinal flora of a newborn mouse can be promoted, long-term influence is generated, and long-term colonitis of the mouse is prevented.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to application of bifidobacterium bifidum from infant intestinal tracts with a preservation number of CGMCC NO. 24517.
Background
Inflammatory bowel disease (Inflammatory bowel disease, IBD), a chronic, non-specific inflammatory disease of the intestinal tract whose etiology is not yet well understood, mainly comprises ulcerative colitis (Ulcerative colitis, UC) and Crohn's Disease (CD). IBD occurs mainly in the colon, often affecting all the colon, limited to the colonic mucosa, and is mainly ulcers and erosions. The pathogenesis of IBD is currently not completely defined, but there may be some key contributors. There is evidence that genetic factors, defective mucosal barrier function, innate and adaptive immunity, and altered microbial composition contribute to the development and progression of IBD. In recent years, the incidence of IBD has been high in European and American countries, with the incidence of UC being about 8/10 ten thousand and the incidence of CD being about 7.8/10 ten thousand. The incidence of IBD in Asia is about 1.37/10 ten thousand, with the incidence in China being about 3.44/10 ten thousand. IBD can be seen as a further important chronic disease that afflicts human health.
IBD patients have been investigated to focus mainly on the young population, with children in western countries and IBD patients in the teenagers increasing year by year, with about 20% -30% of IBD patients diagnosed during childhood or adolescence. Young patients are found to develop chronic inflammatory bowel disease more readily than adult patients, and childhood IBD patients may be at risk for extra-intestinal symptoms such as growth retardation, anemia, joint symptoms, and delayed puberty. Early prevention of IBD is therefore particularly important.
Early life refers to the period of time from the beginning of fetal life to two years after birth. Human intestinal microorganisms begin to colonize from postnatal and gradually develop into adult flora structures, with increased flora diversity. The applicant finds that in the research of allergic diseases, in the construction process of intestinal flora in early life, the change of factors such as environment and the like easily affects the structure and diversity of early intestinal microorganisms, and long-term effect on health conditions and immune functions is generated, so that adult allergic diseases are prevented. The applicant has surprisingly found that the onset of IBD with a certain immune mechanism, like allergic diseases, is also affected by the construction of intestinal flora early in life.
Bifidobacteria are the major components of the human intestinal microbiota and are one of the most important dominant microbiota in the infant intestinal tract. The first week after birth, bifidobacteria begin to colonise the neonatal gut, forming a protective barrier against potential pathogens and stimulating the immune system. Bifidobacterium bifidum (Bifidobacterium bifidum, b.bifidum) is one of the representative species of bifidobacteria in the infant intestinal tract. The study shows that b.bifidum can prevent infantile diarrhea caused by rotavirus and significantly reduce stress-related behavior, and is likely to treat stress-related diseases. There are studies indicating that bifidobacteria promote the development of thymus in infants, thereby enhancing their response to oral administration and injection of vaccines. However, in the prior art, there is no report of improving the construction of early life intestinal flora by bifidobacteria derived from infant intestinal tracts to relieve symptoms of long-term inflammatory bowel disease.
Therefore, the provision of bifidobacteria derived from infant intestinal tracts, which promote the construction of intestinal flora in early life and relieve the symptoms of long-term inflammatory bowel disease, is a problem to be solved urgently by those skilled in the art.
Disclosure of Invention
The invention aims to provide an application of bifidobacterium bifidum from infant intestinal tracts, which solves the problem that bifidobacterium from infant intestinal tracts does not exist in the prior art so as to promote the construction of early-life intestinal flora and relieve symptoms of long-term inflammatory bowel diseases.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
The invention provides application of bifidobacterium bifidum BD-1 from infant intestinal tracts, which has the preservation number of CGMCC NO.24517 and is applied to preparation of medicines or foods with the effect of promoting construction of intestinal flora in early life.
The preservation units of the bifidobacterium bifidum are as follows: the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) has a collection unit address of: the preservation date of the Gao district North Star West Liu 1,3 in Beijing city is: 2022, 03, 11.
In some embodiments of the invention, the use is in the manufacture of a medicament or food having the effect of promoting the establishment of intestinal flora early in life and preventing/alleviating long-term inflammatory bowel disease.
In some embodiments of the present invention, the pharmaceutical or food product comprises bifidobacterium bifidum with a collection number of CGMCC No.24517, and one or more pharmaceutically acceptable carriers.
By "pharmaceutically acceptable carrier" as used herein is meant a diluent, adjuvant, excipient or vehicle with which the therapeutic agent is administered, and which is suitable for contacting the tissues of humans and/or other animals without undue toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, within the scope of sound medical judgment.
In some embodiments of the invention, the pharmaceutical or food product is an oral formulation.
In some embodiments of the invention, the oral formulation comprises a solid oral formulation or a liquid oral formulation.
The bifidobacterium bifidum BD-1 of the present invention was isolated from the intestinal tract of a healthy infant of one year old and identified as bifidobacterium bifidum. Animal experiments show that the bifidobacterium BD-1 is used in early life, so that the construction of intestinal flora of a newborn mouse can be promoted, long-term influence is generated, and long-term colonitis of the mouse is prevented.
Compared with the prior art, the invention has the following beneficial effects:
The invention creatively separates bifidobacteria from intestinal tracts of healthy infants aged one year to obtain bifidobacteria BD-1. Animal experiments show that the bifidobacterium BD-1 is used in early life, so that the construction of intestinal flora of a newborn mouse can be promoted, long-term influence is generated, and long-term colonitis of the mouse is prevented.
Drawings
FIG. 1 is a view of strain BD-1 under a microscope (1000X).
FIG. 2 shows a colony morphology plate of strain BD-1.
FIG. 3 is a phylogenetic tree of strain BD-1.
FIG. 4 is a graph showing the results of inflammatory pathology scoring of mice with DSS-induced colitis, wherein "ns" indicates that p >0.05; ". Times" means p <0.05; "x" means p <0.01; ", denotes p <0.001, n=6-8/group.
FIG. 5 is a graph of colon tissue HE staining of colitis mice, wherein A is the physiological saline-water group and B is the physiological saline-DSS group; c is BD-1-water group; d is BD-1-DSS group.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
This example discloses a method for separating and screening bifidobacterium bifidum BD-1 of the present invention.
1. Isolation of strains from crowd sources
Normal term newborns born at the child-producing hospital at the university Hua Xifu of Sichuan university between 3 and 4 of 2013 were selected as subjects. Inclusion criteria: residing in five urban areas of Chengdu city; the birth weight is 2500-4000 g after 37-42 weeks, and the infant has no congenital abnormality or birth defect. Exclusion criteria: the mother used antibiotics within one month before birth; parents have infectious diseases such as AIDS, tuberculosis, hepatitis B and the like; the neonate cannot collect the feces due to severe diseases such as neonatal pneumonia. The study followed Helsink principles and infants incorporated into the study were given informed consent by their father or mother on their behalf. The collection of faeces from a follow-up infant aged 1 facilitates a sterilized faeces cassette. Immediately after sampling, the sample was stored at 4℃and sent to a laboratory at low temperature by a researcher for dilution culture of the stool sample, and if the sample could not be immediately handled, the sample was stored at 4℃anaerobically and cultured on the same day.
2. Separation of dominant bifidobacteria in specimens
0.5G of excrement is weighed, 4.5mL of excrement diluent is added, and the mixture is stirred and mixed uniformly for serial 10-time dilution. 100 mu L of fecal mixed solution with proper concentration is respectively and evenly coated on a BL plate containing 5% horse blood by an L-shaped glass rod, and cultured for 48-72 h under anaerobic condition at 37 ℃. The total number of anaerobes was counted and suspicious colonies with bifidobacteria characteristics were picked from the high dilution BL plates and inoculated on selective medium TOS plates and placed in anaerobic conditions at 37℃for 48h, based on the remarkable characteristics of bifidobacteria growth on BL plates (brownish in central brown or marginal portion, smooth and moist surface, rounded, bulging, clean edge, diameter about 3-5 mm). The bacteria growing well on TOS plate are selected for gram staining, the form of the bacteria is observed under microscope, microscopic examination is gram positive bacillus, the staining is uneven, one end or two ends are enlarged or forked, no spore exists, and the bacteria are inoculated on MRS plate, after aerobic culture for 48 hours at 37 ℃, the bacteria are completely free of growing, the bacteria are primarily judged to be bifidobacterium, and the bacteria are preserved at-80 ℃ by taking skimmed milk powder as solvent.
Example 2
The bifidobacterium bifidum BD-1 of the invention is sent to China center for identification,
1. The strain is shown in figure 1 and figure 2.
2. 16S rRNA identification is carried out, and the 16S rRNA identification sequence of the strain is shown as SEQ ID NO. 1.
3. The results of BLAST for the 16S rRNA gene sequencing of this strain are shown in Table 1:
TABLE 1
4. The Neighbor-training phylogenetic tree constructed by using Scardovia inopinata DSM10107 (D89332) as an outer branch based on the 16S rRNA gene sequence comparison result is shown in figure 3.
5. The strain of the invention is subjected to physiological and biochemical characteristic detection, the enzyme activity detection result is shown in table 2, and the acid production result by using a carbon source is shown in table 3.
TABLE 2 physiological and biochemical Properties of strain BD-1-enzyme Activity
+: A positive reaction; -: a negative reaction; w: weak positive reaction
TABLE 3 physiological and biochemical characteristics of strain BD-1-acid production Using carbon sources
+: A positive reaction; -: a negative reaction;
Based on the above-described detection results, the strain BD-1 of the present invention was identified as Bifidobacterium bifidum (bifidobacterium bifidum, great name: bacillus bifidus).
Test example 1
The test example discloses an influence test of bifidobacterium bifidum BD-1 of the present invention on the composition of intestinal flora and on the symptoms of colitis.
1 Data and method
1.1 Laboratory animals and reagents
BALB/C mice were purchased from Liaoning Changsheng biotechnology Co., ltd (animal license number: SCXK (Liao) 2020-0001), bred in the animal center of the university of Sichuan China, china public health college (laboratory license number: SYXK (Sichuan) 2018-011), and had an environmental relative humidity of 40% -60%, a room temperature of (22+ -1) deg.C, and a 12-hour day-night cycle, and were free of ordinary drinking water. The feeding conditions were grade without specific pathogen (specific pathogen free, SPF).
The probiotic is Bifidobacterium bifidum BD-1 (Bifidobacterium bifidum BD-1). Each gram of the bacterial powder contains 1250 hundred million live bacteria (the counting unit is CFU).
1.2 Animal Experimental groups
The sex of the obtained novel BALB/C mice is distributed naturally according to birth, and the sex is randomly divided into 4 groups including physiological saline-water group, physiological saline-DSS group, BD-1-water group and BD-1-DSS group, wherein the total number of the groups is about 16. Mice were stopped from postnatal groups, normal saline-water and normal saline-DSS groups were perfused with normal saline (lavage amount 0.2 mL/day) to 3 weeks of age, BD-1-water and BD-1-DSS groups were perfused with BD-1 (absolute bacterial load 10 9 CFU/day, lavage amount 0.2 mL/day) for 3 weeks of age, and half of the mice were sacrificed at each group at 3 weeks of age. When the rest mice continue to be fed with the common feed until the age of 6 weeks, the drinking water of the normal saline-water group and the BD-1-water group is still pure water, and the mice are free to drink for 4 days; the drinking water of the physiological saline-DSS group and BD-1-DSS group is added with 3% dextran sulfate sodium salt (DSS) (molecular weight is 30-50 kDa) to induce colonitis model, and the colonitis model is drunk freely for 4 days. At week 6 for 4 days, the remaining mice were sacrificed and the trial ended. Weekly weight changes were recorded in the experiments, fecal samples were taken from the mice at 3 weeks and 6 weeks for 4 days (end of the experiment), and after animal sacrifice, all the intestinal tissue was collected.
1.3 Method for evaluating pathological section and inflammation condition of colon tissue
Colon tissue samples were collected for 3 weeks and at the end of the experiment. Firstly 10% neutral formalin is soaked and fixed for 2 days, then 60% -70% alcohol is used for soaking, then tissue dehydration and paraffin embedding are carried out, longitudinal slicing is carried out according to intestinal morphology, and finally HE staining is carried out. The pathologist was asked to score the tissue according to pathology scoring criteria. Specific scoring criteria are as follows, and the degree of inflammatory injury [0 points (no injury); 1min (mild); 2 minutes (middle); 3 minutes (severe) ], inflammatory injury depth [0 minutes (intact); score 1 (mucosal layer); score 2 (submucosa); 3 minutes (full layer) ], the area range of the mucosa of inflammatory destruction [1 minute (0-25%); 2 minutes (26% -50%); 3 minutes (51% -75%); 4 points (76% -100%) ], crypt damage degree [0 points (no damage); score 1 (1/3 of the base layer); 2 minutes (2/3 of the base layer); 3 minutes (only intestinal surface epithelium intact); 4 minutes (intestinal epithelium and basal layer are both destroyed) ], the mucosa area range of crypt destruction [1 minute (0-25%); 2 minutes (26% -50%); 3 minutes (51% -75%); score of 4 (76% -100%). And adding the scores of the individual items to obtain a final pathology score, wherein the score range is 1 to 18 points.
1.4 Fecal microorganism sequencing methods
1.4.1 Fecal genomic DNA extraction
Fecal genomic DNA was extracted according to TIANamp Stool DNAKit (cat# DP 328) instructions
1.4.2 Amplicon Generation
Bacterial 16S rRNAV3-V4 region universal primers were selected for PCR amplification of fecal genomic DNA, and the region fragments contained rich bacterial classification information. The universal primers for the 16S rRNAV3-V4 region are 341FCCTAYGGGRBGCASCAG and 806R GGACTACNNGGGTATCTAAT.
1.4.3 Clone sequencing
According toInstructions for DNAPCR-Free sample preparation kit (Illumina, usa) a sample DNA sequencing library was generated, which was sequenced on the IlluminaNovaSeq platform.
1.5 Intestinal microbiota analysis
1.5.1Alpha diversity analysis
The Alpha diversity index may reflect the richness and uniformity of the microbiota composition, and the Shannon index and Simpson index represent uniformity indicators in the sample microbiota diversity.
1.6 Statistical treatment
Statistical analysis was performed using SPSS26.0 software. Metering data conforming to normal distributionAnd (3) representing. The data obey normal distribution and are uniformly distributed, the comparison between two groups adopts t-test, and the comparison between multiple groups adopts one-way analysis of variance (ANOVA). The data do not obey normal distribution or variance disorder, and a t' test or a nonparametric test is adopted. P <0.05 is statistically significant for the differences.
2 Results
2.1 Cases of colitis inflammation in groups of mice at the end of the experiment
After the end of the experiment (4 days at 6 weeks) mice were sacrificed, colon tissues of the mice were HE stained and pathologically scored for inflammation. The results are shown in fig. 4 and table 4: after DSS induction, the mean score for inflammatory pathology in the saline-DSS group was 17.1 score higher than the mean score for saline-water group by 5.3 score, and the mean score for inflammatory pathology in the BD-1-DSS group was 12.3 score higher than the mean score for BD-1-water group by 3.6 score, with the differences all statistically significant (p < 0.05). As shown in FIG. 5, HE stained sections of intestinal tissue from both model groups showed abnormal colonic glandular patterns, with structural damage being more severe, similar to the symptoms of colitis in IBD patients, in the saline-DSS group compared to the saline-water group and in the BD-1-DSS group compared to the BD-1-water group. Indicating successful modeling.
As shown in fig. 4 and table 4, the inflammatory pathological score was significantly reduced in the BD-1-DSS group compared to the saline-DSS group, and the difference was statistically significant (p < 0.05). The HE staining slice result is shown in figure 5, wherein A is physiological saline-water group, and colonic mucosa is normal in morphology and regular in structure; b is a normal saline-DSS group, obvious damage to the crypt structure, gland atrophy, epithelial morphology change and inflammatory infiltration abnormality; c is BD-1-water group, the crypt structure is complete, the gland development is normal, and the structure is regular; d is BD-1-DSS, and shows different degrees of inflammatory response, but crypt destruction and inflammatory infiltration are smaller than those of the saline-water group. Compared with the physiological saline-DSS group, the BD-1-DSS group has less damage to colon crypt structure, lower inflammatory infiltration degree and more complete epithelial structure. The probiotic effect possibly generated by using the bifidobacterium bifidum BD-1 in early life still exists in a period of time after the bacteria are stopped, the intestinal mucosa structure of a long-term mouse can be protected within a certain limit, and the pathological inflammation symptoms of colonitis can be effectively relieved.
Table 4 inflammatory pathology score
Note that: ". Times." indicates p <0.05 compared to saline group; ". Times." means p <0.01 compared to saline group; ", denotes p <0.001 compared to saline group. "#" indicates p <0.05 compared to saline-DSS group; "#" indicates p <0.01 compared to saline-DSS group; "# #" indicates p <0.001 compared to saline-DSS group. n=6-8/group
2.2 Immediate and long-term effects on intestinal flora with BD-1 before 3 weeks
Intestinal flora composition data as in tables 5 and 6 show: at 3 weeks, at the portal level, there was no statistical significance for differences in relative abundance (p > 0.05) between the phylum bacteroides/firmicutes (Bacteroidetes/Firmicutes, B/F) in the group BD-1, but the relative abundance of actinomycota (Actinobacteria) in the group BD-1 was higher than that in the group saline, and the differences were statistically significant (p < 0.05); at the genus level, the relative abundance of bifidobacteria (bifidobacteria) in the BD-1 group was increased compared to the normal saline group, the difference was statistically significant (p < 0.05), the relative abundance of Lactobacillus (Lactobacillus) showed a trend of increasing, the difference was not statistically significant (p > 0.05), but the relative abundance of Enterococcus (Enterococcus) and Staphylococcus (Staphylococcus) were significantly decreased, and the difference was statistically significant (p < 0.05). At the end of the experiment, at the portal level, the difference in relative abundance of B/F was statistically insignificant (p > 0.05) compared to that of BD-1-DSS, but the relative abundance of Proteus (Proteus) was decreased in BD-1, and the difference was statistically significant (p < 0.05); at the genus level, the relative abundance of Lactobacillus in the BD-1-DSS group was increased compared to the saline-DSS group, but the relative abundance of Staphylococcus, ruminococcus (Ruminococcus) and Escherichia/Shigella was decreased, and the differences were statistically significant (p < 0.05).
Table 53 average relative abundance of species at levels of mice intestinal flora at week 53 and end of experiment
Note that: ". Times." indicates p <0.05 compared to saline group; ". Times." means p <0.01 compared to saline group; ", denotes p <0.001 compared to saline group. "#" indicates p <0.05 compared to saline-DSS group; "#" indicates p <0.01 compared to saline-DSS group; "# #" indicates p <0.001 compared to saline-DSS group. n=5/group
Table 6 3 average relative abundance of species at mouse intestinal flora level at week and end of experiment
Note that: ". Times." indicates p <0.05 compared to saline group; ". Times." means p <0.01 compared to saline group; ", denotes p <0.001 compared to saline group. "#" indicates p <0.05 compared to saline-DSS group; "#" indicates p <0.01 compared to saline-DSS group; "# #" indicates p <0.001 compared to saline-DSS group. n=5/group
As shown in table 7, the intestinal flora Alpha diversity data showed that both Shannon index and Simpson index were decreased in BD-1 group compared to saline group at 3 weeks, and the difference was statistically significant (p < 0.05); similarly, at the end of the experiment, the Shannon index and Simpson index were also lower for the BD-1-DSS group than for the saline-DSS group, the differences were statistically significant (p < 0.05).
TABLE 7 intestinal flora Alpha diversity
Note that: ". Times." indicates p <0.05 compared to saline group; ". Times." means p <0.01 compared to saline group; ", denotes p <0.001 compared to saline group. "#" indicates p <0.05 compared to saline-DSS group; "#" indicates p <0.01 compared to saline-DSS group; "# #" indicates p <0.001 compared to saline-DSS group. n=5/group
From the above test results, it is apparent that the BD-1 group used 3 weeks before the present invention had higher relative abundance of beneficial bacteria (e.g., bifidobacterium, lactobacillus) and lower relative abundance of harmful bacteria (e.g., enterococcus and Staphylococcus) than the physiological saline group. After stopping the intervention in the adult period of mice, after inducing colitis with DSS, the BD-1-DSS group still has higher beneficial bacteria (such as Lactobacillus) and lower harmful bacteria (such as Staphylococcus) than the physiological saline-DSS group. In addition, when colitis occurs, BD-1-used neonatal mice have lower ruminococcus in adulthood and Escherichia/Shigella. While ruminococci and adhesion-invasiveness escherichia are closely related to IBD and intestinal inflammation.
The data for gut flora diversity show that both Shannon and Simpson indices were lower in the gut flora of BD-1-interfered mice than in the non-interfered mice at 3 weeks and at the end of the experiment. The Shannon index and Simpson index are indicators representing uniformity in flora diversity, suggesting that BD-1 may relatively increase non-dominant bacteria (e.g., bifidobacteria) in the intestinal tract of neonatal and adult mice, resulting in decreased flora uniformity, similar to the results of intestinal flora composition data.
In conclusion, the possible probiotics effect generated by using BD-1 in early life still exists after bacteria are stopped until the experiment is finished, so that the intestinal mucosa structure of a long-term mouse can be protected within a certain limit, and the pathological inflammation symptoms of colonitis can be effectively relieved. BD-1 can promote the construction of intestinal flora of newborn mice to a certain extent in early stage, so that the relative abundance of beneficial bacteria is increased, and the relative abundance of harmful bacteria is reduced. After the BD-1 is deactivated, the early establishment of a good flora structure can also be sustained until adulthood. When colonitis occurs in the adult stage, the intestinal flora still maintains a state in which there are relatively more beneficial bacteria, relatively fewer harmful bacteria, and fewer inflammation-related flora. Thus, promoting early intestinal flora establishment still has some intestinal anti-inflammatory effect at the end of the adult phase of the probiotic dry prognosis.
Finally, it should be noted that: the above embodiments are merely preferred embodiments of the present invention for illustrating the technical solution of the present invention, but not limiting the scope of the present invention; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the corresponding technical solutions; that is, even though the main design concept and spirit of the present invention is modified or finished in an insubstantial manner, the technical problem solved by the present invention is still consistent with the present invention, and all the technical problems are included in the protection scope of the present invention; in addition, the technical scheme of the invention is directly or indirectly applied to other related technical fields, and the technical scheme is included in the scope of the invention.
Claims (5)
1. The application of bifidobacterium bifidum (Bifidobacterium bifidum) from infant intestinal tracts is characterized in that the preservation number of the bifidobacterium bifidum is CGMCC No. 24517, and the application is the application in preparing medicines or foods with the effect of promoting the construction of intestinal flora in early life.
2. The use according to claim 1, characterized in that it is the use in the preparation of a medicament having the effect of promoting the establishment of intestinal flora early in life and preventing/alleviating inflammatory bowel disease in the long term.
3. The use according to claim 1 or 2, wherein the medicament comprises bifidobacterium bifidum with a collection number of CGMCC No. 24517, and one or more pharmaceutically acceptable carriers.
4. The use according to claim 1 or 2, wherein the medicament is an oral formulation.
5. The use according to claim 4, wherein the oral formulation comprises a solid oral formulation or a liquid oral formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210821655.XA CN116004416B (en) | 2022-07-13 | 2022-07-13 | Application of bifidobacterium bifidum from infant intestinal tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210821655.XA CN116004416B (en) | 2022-07-13 | 2022-07-13 | Application of bifidobacterium bifidum from infant intestinal tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116004416A CN116004416A (en) | 2023-04-25 |
| CN116004416B true CN116004416B (en) | 2024-05-10 |
Family
ID=86025450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210821655.XA Active CN116004416B (en) | 2022-07-13 | 2022-07-13 | Application of bifidobacterium bifidum from infant intestinal tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116004416B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116286439A (en) * | 2022-07-13 | 2023-06-23 | 四川大学 | Bifidobacterium bifidum from infant intestinal tracts and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107485625A (en) * | 2017-07-06 | 2017-12-19 | 南昌大学 | Bifidobacterium bifidum WBBJ01 new opplication |
| CN107629988A (en) * | 2017-11-03 | 2018-01-26 | 江南大学(扬州)食品生物技术研究所 | A kind of bifidobacterium bifidum for alleviating colorectal cancer and application thereof |
| CN112694992A (en) * | 2020-12-30 | 2021-04-23 | 江南大学 | Bifidobacterium bifidum capable of relieving diarrhea and application thereof |
| CN114504110A (en) * | 2022-02-16 | 2022-05-17 | 河南磐康健康管理股份有限公司 | Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof |
| CN114574390A (en) * | 2022-03-09 | 2022-06-03 | 江南大学 | Bifidobacterium longum subspecies of infant for relieving colitis and application |
| CN116286439A (en) * | 2022-07-13 | 2023-06-23 | 四川大学 | Bifidobacterium bifidum from infant intestinal tracts and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2481299T3 (en) * | 2011-01-31 | 2017-02-06 | Dr Fischer Gesundheitsprodukte Gmbh | BIFIDOBACTERIUM BIFIDUM STREAMS FOR USE IN GASTROINTESTINAL DISEASES |
| EP3592370A4 (en) * | 2017-03-10 | 2021-01-20 | Biohm Health LLC | Compositions and methods for promoting a healthy microbial flora in a mammal |
| IT201900011193A1 (en) * | 2019-07-08 | 2021-01-08 | Sofar Spa | Bifidobacterium bifidum strain of bacteria, its compositions and relative uses |
-
2022
- 2022-07-13 CN CN202210821655.XA patent/CN116004416B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107485625A (en) * | 2017-07-06 | 2017-12-19 | 南昌大学 | Bifidobacterium bifidum WBBJ01 new opplication |
| CN107629988A (en) * | 2017-11-03 | 2018-01-26 | 江南大学(扬州)食品生物技术研究所 | A kind of bifidobacterium bifidum for alleviating colorectal cancer and application thereof |
| CN112694992A (en) * | 2020-12-30 | 2021-04-23 | 江南大学 | Bifidobacterium bifidum capable of relieving diarrhea and application thereof |
| CN114504110A (en) * | 2022-02-16 | 2022-05-17 | 河南磐康健康管理股份有限公司 | Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof |
| CN114574390A (en) * | 2022-03-09 | 2022-06-03 | 江南大学 | Bifidobacterium longum subspecies of infant for relieving colitis and application |
| CN116286439A (en) * | 2022-07-13 | 2023-06-23 | 四川大学 | Bifidobacterium bifidum from infant intestinal tracts and application thereof |
Non-Patent Citations (10)
| Title |
|---|
| Bifidobacterium bifidum: A Key Member of the Early Human Gut Microbiota;Francesca Turroni等;《Microorganisms》;20191109;第7卷(第11期);全文 * |
| Colonization of C57BL/6 Mice by a Potential Probiotic Bifidobacterium bifidum Strain under Germ-Free and Specific Pathogen-Free Conditions and during Experimental Colitis;Grimm V等;《Plos One》;20151006;第10卷;全文 * |
| Early life administration of Bifidobacterium bifidum BD-1 alleviates long-term colitis by remodeling the gut microbiota and promoting intestinal barrier development;Chenrui Peng等;《Front Microbiol》;20220722;全文 * |
| Potential of Lactobacillus plantarum ZDY2013 and Bifidobacterium bifidum WBIN03 in relieving colitis by gut microbiota, immune, and anti-oxidative stress;Wang YY等;《Canadian Journal of Microbiology》;20180205;第64卷(第5期);第327-337页 * |
| 两歧双歧杆菌TMC3115促进生命早期肠道菌群构建及其对远期炎症性肠病的影响;彭晨芮等;《四川大学学报（医学版）》;20220812;第53卷(第5期);第834-841页 * |
| 健康婴儿与过敏性疾病婴儿肠道双歧杆菌构建差异初探;王茂林;沈曦;葛林;何苗;李鸣;姚建蓉;何方;;中国当代儿科杂志;20180906(第09期);全文 * |
| 双歧杆菌及其产品缓解肠炎症状的研究进展;孙庆申;罗钦文;许艳玲;;乳业科学与技术;20200701(第04期);全文 * |
| 新生儿坏死性小肠结肠炎相关研究现状;周波;唐军;;中华妇幼临床医学杂志(电子版);20180401(第02期);全文 * |
| 生命早期使用头孢曲松对小鼠后期糖脂代谢的影响及两歧双歧杆菌TMC3115的改善效果研究;周玮忻等;《中国抗生素杂志》;20200618;第45卷(第9期);第947-952页 * |
| 益生菌在新生儿坏死性小肠结肠炎中的应用;郭城;张琳;;中国实用儿科杂志;20170206(第02期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116004416A (en) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201143631A (en) | Novel Enterococcus faecium LJS-01 and its use as probiotic | |
| EP2522358A1 (en) | Peptides against rotavirus infection | |
| US11458177B2 (en) | Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same | |
| CN115216422B (en) | Lactobacillus rhamnosus and application thereof | |
| CN116004416B (en) | Application of bifidobacterium bifidum from infant intestinal tract | |
| CN116083300B (en) | Probiotic composite preparation for preventing and treating canine diarrhea and application thereof | |
| CN111117925B (en) | Anerostipes sp B2131 bacterium and application thereof in inflammatory bowel disease | |
| CN115505551B (en) | Lactobacillus helveticus and application thereof in preventing or treating nephritis | |
| CN113122466A (en) | Enterococcus faecalis and application thereof | |
| Ma et al. | Poly-β-hydroxybutyrate alleviated diarrhea and colitis via Lactobacillus johnsonii biofilm-mediated maturation of sulfomucin | |
| CN114806978B (en) | Lactobacillus johnsonii SXDT-23 and application thereof | |
| EP3584314A1 (en) | Novel pseudomonas aeruginosa bacteriophage pse-aep-3 and use thereof for inhibiting proliferation of pseudomonas aeruginosa | |
| EP3584315A1 (en) | Novel pseudomonas aeruginosa bacteriophage pse-aep-4 and use thereof for inhibiting proliferation of pseudomonas aeruginosa | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| CN117106672B (en) | Bifidobacterium breve for improving aging-related cognitive impairment and application thereof | |
| CN117264814A (en) | Lactobacillus rhamnosus with effects of preventing and treating digestive tract diseases | |
| CN116396909A (en) | Lactobacillus plantarum X86 for resisting staphylococcus aureus mastitis | |
| CN116286439A (en) | Bifidobacterium bifidum from infant intestinal tracts and application thereof | |
| CN116121122B (en) | Probiotic composite preparation for preventing and treating diarrhea of cats and application thereof | |
| CN114806962B (en) | Bacteroides xylanisolvens AY11-1 and application thereof in preparation of medicines and health-care foods for treating inflammatory bowel diseases | |
| CN116083286B (en) | Bifidobacterium infantis B8762 and application thereof in preparation of probiotic preparation | |
| CN114921378B (en) | Enterococcus faecium and application of composite preparation thereof in relieving ulcerative colitis | |
| CN116200313B (en) | Lactobacillus salivarius and application thereof | |
| CN115125163B (en) | Lactobacillus casei and application thereof | |
| CN115433700B (en) | Arthrobacter sakei and application thereof in preparation of medicines for preventing and treating inflammatory bowel diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |